Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT07001735
Recruiting Not applicable

Talking for Change: Secondary Prevention of Child Sexual Abuse Perpetration

NCT07001735 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2025-04-17
Last updated
2025-06-12

Condition(s) studied

PedophiliaHebephiliaChild Sexual AbuseProgram EvaluationPrevention InterventionParaphilias and Paraphilic Disorders

Investigational drug(s) / intervention(s)

Talking for Change Group PsychotherapyHealthier Me: Managing Risk and Stress in Everyday Life

Talking for Change Group Psychotherapy: Talking for Change (TFC) is a secondary prevention program that targets dynamic risk factors for child sexual abuse, including (1) atypical sexual interests and sexual self-regulation problems; (2) problems in relationships; (3) offense-supportive attitudes; and (4) general self-regulation deficits and related traits (e.g., impulsivity, emotion regulation deficits). Participants will complete 20 weekly, 120-minute sessions delivered via WebEx.

Healthier Me: Managing Risk and Stress in Everyday Life: The active therapeutic control is a non-directive supportive psychotherapy that targets general mental health concerns. It consists of psychoeducation about human sexuality and common mental health concerns, as well as instruction and practice in applied relaxation and stress management, and group discussions that will facilitate sharing and problem-solving current stressors. This active control intervention is equivalent in length to Talking for Change (TFC), consisting of 120-minute long occurring weekly over the course of 20 weeks.

Study summary

The goal of this patient preference randomized controlled trial is to investigate the efficacy of Talking for Change (TFC), an intervention for the secondary prevention of child sexual abuse and exploitation (CSA) perpetration. Blinded clinical raters will evaluate the primary endpoint-reductions in dynamic risk factors for sexual offending against children-and clients will provide self-reports to evaluate a second primary outcome-reductions in sexual contact with children, accessing online child sexual exploitation material (CSEM), and desire for sexual contact with children. Researchers will compare the following groups: (1) those receiving 20 weeks of the experimental TFC group psychotherapy; (2) those receiving 20 weeks of a control group psychotherapy targeting mental health and stress more broadly; and (3) those receiving no treatment.

Eligibility

Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
INCLUSION CRITERIA: For the treatment arms, the participant must meet all of the inclusion criteria to eligible for this clinical trial: 1. Must be deemed to have capacity to provide informed consent; 2. Must sign and date the informed consent form; 3. Stated willingness to comply with all study procedures; 4. Be 18 years of age or older upon study commencement; 5. Be referred for care in the TFC program due to concerns about enhanced risk of sexual offending against children. For the benchmarking interview arm, the participant must meet all of the following inclusion criteria: 1. Must self-report concerns about enhanced risk of sexual offending against children 2. Must be deemed to have capacity to provide informed consent; 3. Must check the appropriate box on the informed consent form; 4. Stated willingness to comply with all study procedures; 5. Be 18 years of age or older upon study commencement. For the benchmarking survey arm, participants must check the appropriate box on the informed consent form. EXCLUSION CRITERIA: For the treatment arms: 1. Inability to engage meaningfully in group psychotherapy (e.g., due to intellectual disability, other neurodiversity, active psychosis or substance use) 2. Those who self-identify as at-risk for reasons better accounted for by non-risk-relevant factors per clinical assessment (e.g., those with obsessive-compulsive disorder including thoughts about CSA, who commonly fear that they are at-risk but are not). 3. Non-male sex. For the benchmarking interview arm: 1\. Non-male sex.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Centre for Addiction and Mental Health Toronto Ontario Recruiting

More Centre for Addiction and Mental Health trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07001735 on ClinicalTrials.gov ↗ ← All trials in Canada